Table 2 Baseline characteristics before and after propensity score matching
Characteristics | Before matching | After macthing | ||||
|---|---|---|---|---|---|---|
ARB users (n = 922) | CCB users (n = 731) | p value | ARB users (n = 601) | CCB users p value | (n = 601) | |
Age (mean, SE) | 61.7 ± 0.4 | 66.8 ± 0.35 | <.0001 * | 65.5 ± 0.4 | 65.6 ± 0.39 | 0.8268 |
Age over 75 years | 130 (14.1%) | 158 (21.6%) | <.0001 * | 110 (18.3%) | 113 (18.8%) | 0.8238 |
Women | 316 (34.3%) | 281 (38.4%) | 0.0798 | 224 (37.3%) | 225 (37.4%) | 0.9525 |
Medical history | ||||||
 Cerebrovascular disease | 254 (27.5%) | 208 (28.5%) | 0.6837 | 170 (28.3%) | 185 (30.8%) | 0.3429 |
 Ischemic heart disease | 317 (34.4%) | 297 (40.6%) | 0.009 * | 228 (37.9%) | 233 (38.8%) | 0.7668 |
 Other heart disease | 208 (22.6%) | 193 (26.4%) | 0.0703 | 156 (26.0%) | 149 (34.8%) | 0.6427 |
 Gout | 28 (3.0%) | 43 (5.9%) | 0.0046 * | 25 (4.2%) | 25 (4.2%) | 1 |
 Thyroid disorder | 266 (28.9%) | 155 (21.2%) | 0.0004 * | 141 (23.5%) | 142 (23.6%) | 0.9458 |
 Rheumatoid arthritis | 85 (9.2%) | 68 (9.3%) | 0.9538 | 48 (8.0%) | 51 (8.5%) | 0.753 |
 Liver disease | 481 (52.2%) | 404 (55.3%) | 0.2098 | 327 (54.4%) | 316 (52.6%) | 0.5247 |
 Kidney disease | 688 (74.6%) | 483 (66.1%) | 0.0001 * | 407 (67.7%) | 411 (68.4%) | 0.8046 |
 Hyperlipidemia | 860 (93.3%) | 678 (92.7%) | 0.6764 | 559 (93.0%) | 561 (93.3%) | 0.819 |
 Proteinuria | 463 (50.2%) | 298 (40.8%) | 0.0001 * | 255 (42.4%) | 256 (42.6%) | 0.9535 |
Previous drugs | ||||||
 Hypoglycemic drugs | 226 (24.5%) | 188 (25.7%) | 0.574 | 148 (24.6%) | 156 (26.0%) | 0.5955 |
  Insulin | 79 (8.6%) | 44 (6.0%) | 0.0498 * | 36 (6.0%) | 42 (7.0%) | 0.4823 |
  Oral hypoglycemic drugs | 171 (18.5%) | 160 (21.9%) | 0.0918 | 126 (21.0%) | 129 (21.5%) | 0.8324 |
 Lipid-lowering drugs | 339 (36.8%) | 237 (32.4%) | 0.0655 | 201 (33.4%) | 200 (33.3%) | 0.9512 |
  Statin | 286 (31.0%) | 200 (27.4%) | 0.1048 | 171 (28.5%) | 169 (28.1%) | 0.8981 |
  Fibrate | 36 (3.9%) | 29 (4.0%) | 0.9481 | 21 (3.5%) | 23 (3.8%) | 0.7587 |
  Other lipid-lowering drugs | 30 (3.3%) | 23 (3.1%) | 0.902 | 18 (3.0%) | 18 (3.0%) | 1 |
 Diuretics | 7 (0.8%) | 1 (0.1%) | 0.0701 | 1 (0.2%) | 1 (0.2%) | 1 |
 Immunosuppressive drugs | 14 (1.5%) | 10 (1.4%) | 0.7995 | 5 (0.8%) | 8 (1.3%) | 0.4028 |
 Gout drugs | 59 (6.4%) | 86 (11.8%) | 0.0001 * | 48 (8.0%) | 51 (8.5%) | 0.753 |
 Potassium preparations | 2 (0.2%) | 4 (0.5%) | 0.2674 | 1 (0.2%) | 0 (0%) | 0.3171 |
 Antipsychotics | 38 (4.1%) | 19 (2.6%) | 0.0921 | 18 (3.0%) | 17 (2.8%) | 0.8638 |
 Chemotherapeutic drugs | 14 (1.5%) | 18 (2.5%) | 0.1666 | 11 (1.8%) | 9 (1.5%) | 0.652 |
 Steroids | 57 (6.2%) | 43 (5.9%) | 0.7995 | 32 (5.3%) | 33 (5.5%) | 0.8985 |
 NSAIDs | 284 (30.8%) | 236 (32.3%) | 0.5193 | 181 (30.1%) | 190 (31.6%) | 0.5741 |
 Proton pump inhibitors | 126 (13.7%) | 82 (11.2%) | 0.136 | 77 (12.8%) | 75 (12.5%) | 0.8622 |
 H2 blockers | 120 (13.0%) | 144 (19.7%) | 0.0002 * | 93 (15.5%) | 100 (16.6%) | 0.5824 |
 Thyroid drugs | 12 (1.3%) | 13 (1.8%) | 0.4301 | 10 (1.7%) | 9 (1.5%) | 0.8171 |